Publications en collaboration avec des chercheurs de Hospital Clinic Barcelona (68)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  2. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

2023

  1. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  2. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution

    Clinical and Translational Oncology, Vol. 24, Núm. 2, pp. 319-330

  3. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71

  4. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Journal for immunotherapy of cancer, Vol. 10, Núm. 9

2021

  1. Association between coffee consumption and total dietary caffeine intake with cognitive functioning: cross-sectional assessment in an elderly Mediterranean population

    European Journal of Nutrition, Vol. 60, Núm. 5, pp. 2381-2396

  2. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8

  3. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1272-1280

  4. Electronic health records and patient registries in medical oncology departments in Spain

    Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108

  5. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  6. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 2, pp. 135.e17-135.e23

  7. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

    Nature Communications, Vol. 12, Núm. 1

  8. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

    Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936

  9. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  10. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  11. Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890

  12. SEOM clinical guideline for management of adult medulloblastoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148